Replies to post #117664 on Biotech Values

[mcbio]

How could anyone vote that ACHN and INHX were winners? Their drugs didn't surprise anyone or substantially change their valuation.

Even if it didn't change the valuation to any large degree, I think it was pretty important for ACHN that ACH-1625 passed its safety test at 28 days. Efficacy was probably as expected but one never knows with respect to safety. Any untoward safety signal for 1625 at 28 days would have crushed the stock. The same can be said for the 3-month data that is due at the end of this year.

[DewDiligence]

Analysts are turning into not-so cheap prostitutes.

Just to be clear: The people Schoenebaum surveyed about EASL were buy-side analysts, i.e. people who actually own (or sell short) some of these stocks.